BOOK
Contemporary Issues in Patients with Implantable Devices, An Issue of Cardiac Electrophysiology Clinics, E-Book
Amin Al-Ahmad | Raymond Yee | Mark Link
(2018)
Additional Information
Book Details
Abstract
This issue of Cardiac Electrophysiology Clinics--edited by Drs. Amin Al-Ahmad, Raymond Yee, and Mark Link--will focus on Contemporary Issues in Patients with Implantable Devices. Topics include, but are not limited to: Management of Device infections; Device longevity; Inappropriate ICD therapies; ILR for cryptogenic stroke; ICD implantation without DFT testing; S-ICD; Lead extraction; Use of the WCD as a bridge to ICD; Important parameters for ICD selection; Leadless pacemakers; Management of perioperative anticoagulation for device implantation; HIS bundle pacing; Single coil ICD leads; Venous system interventions for device implantation; and Remote monitoring.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Contemporary Issues in Patients with Implantable Devices\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITORS | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Foreword: Cardiac Implantable Electronic Devices | vii | ||
| Preface: Contemporary Review of the Cardiovascular Implantable Electronic Devices with Future Directions | vii | ||
| Longevity of Cardiovascular Implantable Electronic Devices | vii | ||
| Use of the Wearable Cardioverter Defibrillator as a Bridge to Implantable Cardioverter Defibrillator | vii | ||
| Leadless Pacemakers: State of the Art and Future Perspectives | vii | ||
| Right Ventricular Pacing and Cardiac Resynchronization Devices | vii | ||
| Remote Monitoring for Chronic Disease Management: Atrial Fibrillation and Heart Failure | viii | ||
| Should Single-Coil Implantable Cardioverter Defibrillator Leads Be Used in all Patients? | viii | ||
| Causes and Prevention of Inappropriate Implantable Cardioverter-Defibrillator Shocks | viii | ||
| When is Device-Detected Atrial Fibrillation Actionable? | viii | ||
| His Bundle Pacing: Is It Ready for Prime Time? | ix | ||
| Management of Perioperative Anticoagulation for Device Implantation | ix | ||
| Implantable Loop Recorders for Cryptogenic Stroke (Plus Real-World Atrial Fibrillation Detection Rate with Implantable Loop ... | ix | ||
| Implantable Cardioverter Defibrillator Implantation with or Without Defibrillation Testing | ix | ||
| Lead Management and Lead Extraction | x | ||
| When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion? | x | ||
| Important Parameters for Implantable Cardioverter Defibrillator Selection | x | ||
| Management of Device Infections | x | ||
| Venous System Interventions for Device Implantation | xi | ||
| CARDIAC ELECTROPHYSIOLOGY CLINICS\r | xii | ||
| FORTHCOMING ISSUES | xii | ||
| June 2018 | xii | ||
| September 2018 | xii | ||
| December 2018 | xii | ||
| RECENT ISSUES | xii | ||
| December 2017 | xii | ||
| September 2017 | xii | ||
| June 2017 | xii | ||
| Foreword: Cardiac Implantable Electronic Devices\r\r | xiii | ||
| Preface:\rContemporary Review of the Cardiovascular Implantable Electronic Devices with Future Directions | xv | ||
| Longevity of Cardiovascular Implantable Electronic Devices | 1 | ||
| Key points | 1 | ||
| INTRODUCTION | 1 | ||
| HISTORICAL PERSPECTIVE | 1 | ||
| EARLY POWER SOURCES | 2 | ||
| LITHIUM AS A POWER SOURCE | 2 | ||
| BATTERY LONGEVITY | 2 | ||
| SUPPLY-SIDE FACTORS | 3 | ||
| Battery Capacity | 3 | ||
| Battery Chemistry | 3 | ||
| Battery Architecture | 3 | ||
| DEMAND-SIDE FACTORS | 4 | ||
| Background Current | 4 | ||
| Radiofrequency Telemetry | 4 | ||
| Electrogram Storage | 4 | ||
| Capacitor Reformation | 4 | ||
| Pacing Output | 5 | ||
| Pacing Impedance | 5 | ||
| Practical Considerations in Choosing Pacing Vector and Output | 5 | ||
| Strength-Duration Curves | 6 | ||
| High-Voltage Therapy | 7 | ||
| SPECIAL SCENARIOS | 7 | ||
| Leadless Cardiac Pacing and Subcutaneous Implantable Cardioverter-Defibrillator | 7 | ||
| Lithium Cluster Formation | 7 | ||
| SUMMARY | 8 | ||
| REFERENCES | 8 | ||
| Use of the Wearable Cardioverter Defibrillator as a Bridge to Implantable Cardioverter Defibrillator | 11 | ||
| Key points | 11 | ||
| INTRODUCTION | 11 | ||
| THE WEARABLE CARDIOVERTER DEFIBRILLATOR | 11 | ||
| SENSING AND SHOCK EFFICACY | 12 | ||
| PATIENT COMPLIANCE | 12 | ||
| WEARABLE CARDIOVERTER DEFIBRILLATOR CLINICAL STUDIES | 12 | ||
| POTENTIAL WEARABLE CARDIOVERTER DEFIBRILLATOR INDICATIONS | 13 | ||
| After Myocardial Infarction | 13 | ||
| TEMPORARY IMPAIRMENT OF LEFT VENTRICULAR FUNCTION | 14 | ||
| After Implantable Cardioverter Defibrillator Extraction | 15 | ||
| DECISION MAKING AND THE WEARABLE CARDIOVERTER DEFIBRILLATOR | 15 | ||
| SUMMARY | 15 | ||
| REFERENCES | 16 | ||
| Leadless Pacemakers | 17 | ||
| Key points | 17 | ||
| INTRODUCTION | 17 | ||
| PACEMAKER TECHNOLOGY: HISTORICAL CONSIDERATIONS AND STATISTICS | 18 | ||
| TECHNOLOGICAL FEATURES OF CURRENTLY AVAILABLE SINGLE-COMPONENT LEADLESS PACEMAKERS | 18 | ||
| Technological Aspects | 18 | ||
| Implantation Technique | 20 | ||
| SAFETY AND EFFICACY OF SINGLE-COMPONENT LEADLESS PACEMAKERS | 20 | ||
| Clinical Data for the Nanostim Leadless Pacemaker System | 20 | ||
| Clinical Data for the Micra Transcatheter Pacing System | 22 | ||
| Patients with Limited Upper Venous Access or/and Contraindications for Traditional Pacing | 23 | ||
| Complications and the Impact of Operator Experience | 24 | ||
| Comparison between leadless systems | 24 | ||
| Comparison between leadless and transvenous systems | 25 | ||
| Acute and Chronic Retrievability | 25 | ||
| Nanostim system retrieval | 26 | ||
| Micra system retrieval | 26 | ||
| SAFETY AND EFFICACY OF MULTICOMPONENT LEADLESS PACEMAKERS | 26 | ||
| SUMMARY | 27 | ||
| REFERENCES | 27 | ||
| Right Ventricular Pacing and Cardiac Resynchronization Devices | 31 | ||
| Key points | 31 | ||
| INTRODUCTION | 31 | ||
| WHAT IS THE SEQUENCE OF NORMAL EXCITATION OF THE HUMAN HEART? | 31 | ||
| HOW IS VENTRICULAR CONDUCTION DERANGED IN RIGHT VENTRICULAR PACING? | 32 | ||
| WHAT ARE THE CLINICAL SEQUELAE OF CHRONIC RIGHT VENTRICULAR PACING? | 32 | ||
| HOW DOES VENTRICULAR ACTIVATION IN CARDIAC RESYNCHRONIZATION THERAPY RESTORE PHYSIOLOGIC ACTIVATION OF THE LEFT VENTRICLE? | 34 | ||
| DO ALL PATIENTS RECEIVING CARDIAC RESYNCHRONIZATION THERAPY FOR PACING-INDUCED CARDIOMYOPATHY RETURN TO NORMAL LEFT VENTRIC ... | 34 | ||
| IS THERE A THRESHOLD OF RIGHT VENTRICULAR PACING BURDEN THAT PREDICTS DEVELOPMENT OF PACING-INDUCED CARDIOMYOPATHY? | 35 | ||
| IF HIGH PACING BURDEN IS ASSOCIATED WITH PACING-INDUCED CARDIOMYOPATHY, SHOULD ALL PATIENTS UNDERGOING ATRIOVENTRICULAR NOD ... | 37 | ||
| WHAT FACTORS IN ADDITION TO RIGHT VENTRICULAR PACING BURDEN CONTRIBUTE TO DEVELOPMENT OF PACING-INDUCED CARDIOMYOPATHY? | 37 | ||
| WHAT IS THE BENEFIT OF CARDIAC RESYNCHRONIZATION THERAPY DEVICES IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION? | 37 | ||
| DO CARDIAC RESYNCHRONIZATION THERAPY DEVICES BENEFIT PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AND A NORMAL QRS DURATION? | 37 | ||
| DOES CARDIAC RESYNCHRONIZATION THERAPY BENEFIT PATIENTS WITH PRESERVED LEFT VENTRICULAR FUNCTION AND A HIGH PACING BURDEN? | 38 | ||
| WHAT ADDITIONAL PROCEDURAL RISKS ARE INVOLVED WITH IMPLANTATION OF A CARDIAC RESYNCHRONIZATION THERAPY DEVICE? | 38 | ||
| FUTURE DIRECTIONS | 39 | ||
| A SIMPLIFIED APPROACH | 39 | ||
| SUMMARY | 40 | ||
| REFERENCES | 40 | ||
| Remote Monitoring for Chronic Disease Management | 43 | ||
| Key points | 43 | ||
| INTRODUCTION | 43 | ||
| REMOTE MONITORING AND ATRIAL FIBRILLATION | 44 | ||
| Current Evidence About Device-Detected Atrial Fibrillation | 44 | ||
| Current Evidence About Remote Monitoring and Atrial Fibrillation | 44 | ||
| Remote Monitoring for Atrial Fibrillation: Beyond Anticoagulation Decisions | 47 | ||
| REMOTE MONITORING AND HEART FAILURE | 47 | ||
| Current Evidence About Remote Monitoring and Heart Failure | 47 | ||
| Important Aspects When Evaluating Heart Failure and Remote Monitoring | 55 | ||
| CURRENT GUIDELINES | 55 | ||
| FUTURE DIRECTIONS | 55 | ||
| REFERENCES | 55 | ||
| Should Single-Coil Implantable Cardioverter Defibrillator Leads Be Used in all Patients? | 59 | ||
| Key points | 59 | ||
| INTRODUCTION | 59 | ||
| EFFICACY | 60 | ||
| Differences in Defibrillation Threshold | 60 | ||
| Right-Sided Pulse Generators | 60 | ||
| RISK | 60 | ||
| Transvenous Lead Extraction Outcomes | 60 | ||
| Mortality | 63 | ||
| SUMMARY | 64 | ||
| REFERENCES | 64 | ||
| Causes and Prevention of Inappropriate Implantable Cardioverter-Defibrillator Shocks | 67 | ||
| Key points | 67 | ||
| INTRODUCTION | 67 | ||
| EPIDEMIOLOGY | 67 | ||
| ETIOLOGIES OF INAPPROPRIATE SHOCKS | 68 | ||
| CONSEQUENCES OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR SHOCKS | 70 | ||
| PREVENTION OF APPROPRIATE AND INAPPROPRIATE IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR SHOCKS | 71 | ||
| Implantable Cardioverter-Defibrillator Programming | 71 | ||
| Medical Therapy | 72 | ||
| Cardiac Rehabilitation | 72 | ||
| SUMMARY | 72 | ||
| REFERENCES | 73 | ||
| When is Device-Detected Atrial Fibrillation Actionable? | 75 | ||
| Key points | 75 | ||
| PREVALENCE AND ACCURACY OF ATRIAL HIGH-RATE EPISODES | 76 | ||
| ATRIAL HIGH-RATE EPISODES AND STROKE RISK | 77 | ||
| CLINICAL MANAGEMENT OF ATRIAL HIGH-RATE EPISODES | 80 | ||
| SUMMARY AND FUTURE DIRECTIONS | 82 | ||
| REFERENCES | 82 | ||
| His Bundle Pacing | 87 | ||
| Key points | 87 | ||
| INTRODUCTION | 87 | ||
| BACKGROUND | 87 | ||
| PHYSIOLOGY | 88 | ||
| IMPLANT TECHNIQUE | 89 | ||
| CLINICAL BENEFITS | 90 | ||
| CASE EXAMPLES | 92 | ||
| LIMITATIONS | 94 | ||
| FUTURE DIRECTIONS | 96 | ||
| REFERENCES | 97 | ||
| Management of Perioperative Anticoagulation for Device Implantation | 99 | ||
| Key points | 99 | ||
| SCOPE OF THE PROBLEM | 100 | ||
| THROMBOEMBOLIC RISK | 100 | ||
| TO BRIDGE OR NOT TO BRIDGE | 101 | ||
| BEFORE OR AFTER | 103 | ||
| EARLY RANDOMIZED CONTROLLED TRIALS | 103 | ||
| META-ANALYSES | 103 | ||
| BRIDGE OR CONTINUE COUMADIN FOR DEVICE SURGERY RANDOMIZED CONTROLLED TRIAL | 104 | ||
| ADDITIONAL COMPLICATIONS | 104 | ||
| FORGOING ANTICOAGULATION ALTOGETHER | 105 | ||
| LOW-RISK PATIENTS | 105 | ||
| DIRECT ORAL ANTICOAGULANTS | 105 | ||
| ANTIPLATELET AGENTS | 106 | ||
| SUMMARY | 107 | ||
| REFERENCES | 107 | ||
| Implantable Loop Recorders for Cryptogenic Stroke (Plus Real-World Atrial Fibrillation Detection Rate with Implantable Loop ... | 111 | ||
| Key points | 111 | ||
| REFERENCES | 117 | ||
| Implantable Cardioverter Defibrillator Implantation with or Without Defibrillation Testing | 119 | ||
| Key points | 119 | ||
| INTRODUCTION | 119 | ||
| METHODS OF DEFIBRILLATION TESTING | 120 | ||
| DETERMINANTS OF DEFIBRILLATION TESTING RESULTS | 121 | ||
| CLINICAL VALUE OF DEFIBRILLATION TESTING | 121 | ||
| SPECIFIC SITUATIONS THAT WARRANT CONSIDERATION OF DEFIBRILLATION TESTING | 123 | ||
| SUMMARY | 124 | ||
| REFERENCES | 124 | ||
| Lead Management and Lead Extraction | 127 | ||
| Key points | 127 | ||
| INDICATIONS FOR EXTRACTION | 127 | ||
| FACILITY REQUIREMENTS | 129 | ||
| PREPARATION FOR THE EXTRACTION PROCEDURE | 130 | ||
| Evaluation of the Cardiac Implantable Electronic Device System | 130 | ||
| Evaluation of the Patient | 130 | ||
| Preparation of the Operating Room | 130 | ||
| Preparation of the Patient | 131 | ||
| Lead Extraction Procedure | 131 | ||
| Complications | 134 | ||
| SUMMARY | 136 | ||
| REFERENCES | 136 | ||
| When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion? | 137 | ||
| Key points | 137 | ||
| CURRENT INDICATIONS FOR IMPLANTABLE CARDIOVERTER DEFIBRILLATORS | 138 | ||
| DATA ON IMPLANTABLE CARDIOVERTER DEFIBRILLATORS | 138 | ||
| DATA ON CARDIAC RESYNCHRONIZATION THERAPY-DEFIBRILLATOR | 140 | ||
| SUMMARY | 142 | ||
| REFERENCES | 142 | ||
| Important Parameters for Implantable Cardioverter Defibrillator Selection | 145 | ||
| Key points | 145 | ||
| INTRODUCTION | 145 | ||
| SINGLE- VERSUS DUAL-CHAMBER IMPLANTABLE CARDIOVERTER DEFIBRILLATOR | 145 | ||
| Arrhythmia Discrimination | 146 | ||
| Detection of Atrial Arrhythmias | 147 | ||
| Antitachycardia Pacing to Treat Atrial Arrhythmias | 147 | ||
| Device-Related Complications | 147 | ||
| Potential Increased Right Ventricle Pacing | 147 | ||
| IMPLANTABLE CARDIOVERTER DEFIBRILLATORS SYSTEM LONGEVITY | 148 | ||
| Lead Durability | 148 | ||
| Generator Longevity | 148 | ||
| IMPLANTABLE CARDIOVERTER DEFIBRILLATORS LEAD | 149 | ||
| PATIENT CHARACTERISTICS | 150 | ||
| SUMMARY | 150 | ||
| REFERENCES | 150 | ||
| Management of Device Infections | 153 | ||
| Key points | 153 | ||
| INTRODUCTION | 153 | ||
| PATHOGENESIS AND MICROBIOLOGY | 153 | ||
| EPIDEMIOLOGY (INCIDENCE AND RISK FACTORS) | 154 | ||
| CLINICAL PRESENTATION AND DIAGNOSIS | 154 | ||
| MANAGEMENT | 156 | ||
| PREVENTION OF CARDIAC IMPLANTABLE ELECTRONIC DEVICE INFECTION | 159 | ||
| Preoperative Prevention | 159 | ||
| Operative Prevention | 159 | ||
| Postoperative Prevention | 160 | ||
| EMERGING CONSIDERATIONS | 160 | ||
| REFERENCES | 160 | ||
| Venous System Interventions for Device Implantation | 163 | ||
| Key points | 163 | ||
| INTRODUCTION | 163 | ||
| EPIDEMIOLOGY | 164 | ||
| PATHOPHYSIOLOGY OF SUBCLAVIAN OCCLUSIONS | 164 | ||
| SAFETY AND EFFICACY OF SUBCLAVIAN VENOPLASTY | 164 | ||
| Step-by-Step Approach to Subclavian Venoplasty | 165 | ||
| BALLOON OPTIONS | 168 | ||
| FOCUSED FORCE VENOPLASTY | 170 | ||
| FACTORS THAT MAKE A SUBCLAVIAN OCCLUSION DIFFICULT TO CROSS | 171 | ||
| COMBINING RETAINED WIRE LEAD REMOVAL AND VENOPLASTY | 171 | ||
| SUBCLAVIAN VENOPLASTY: QUALITY OF VENOUS ACCESS, LEAD BURDEN, AND PRESERVATION OF VENOUS ACCESS | 175 | ||
| SUPPLEMENTARY DATA | 176 | ||
| REFERENCES | 176 |